Neil Bander

Corporate Officer/Principal at DNIB UNWIND INC

Health Technology

Profile

Neil H.
Bander is the founder of Convergent Therapeutics, Inc. and Xenimmune Therapeutics, Inc. He is currently a member of the Scientific Advisory Board at DNIB Unwind, Inc.

Neil Bander active positions

Companies	Position	Start
DNIB UNWIND INC	Corporate Officer/Principal	-
Convergent Therapeutics, Inc. Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation.	Founder	-
Xenimmune Therapeutics, Inc. Xenimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xenimmune Therapeutics, Inc. develops antibody-enzyme fusion to target tumors and trigger the hyper-acute rejection. The private company is located in the US.	Founder	-

All active positions of Neil Bander

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Neil Bander's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	3
DNIB Unwind, Inc. DNIB Unwind, Inc. BiotechnologyHealth Technology DNIB Unwind, Inc. develops biopharmaceutical preparations. The company was founded by Omid C. Farokhzad and Robert S. Langer on May 19, 2006 and is headquartered in Los Angeles, CA.	Health Technology
Convergent Therapeutics, Inc. Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation.	Health Technology
Xenimmune Therapeutics, Inc. Xenimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xenimmune Therapeutics, Inc. develops antibody-enzyme fusion to target tumors and trigger the hyper-acute rejection. The private company is located in the US.	Health Technology

See company connections